Replies to post #33996 on Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Ariad will start a pivotal registration trial for FDA approval of '113 in patients with NSCLC ALK+ in the 3rd quarter of 2013. This is obviously a new trial. In addition, they are continuing the phase 1/II trials of '113 in the 4 or 5 coharts.. Don't have time to look them up for you, but they are in the Ariad press releases.